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Abstract
Background: Hepatitis C virus (HCV) is a common and highly morbid illness. New medications that have much
higher cure rates have become the new evidence-based practice in the field. Understanding the implementation of
these new medications nationally provides an opportunity to advance the understanding of the role of
implementation strategies in clinical outcomes on a large scale. The Expert Recommendations for Implementing
Change (ERIC) study defined discrete implementation strategies and clustered these strategies into groups. The
present evaluation assessed the use of these strategies and clusters in the context of HCV treatment across the US
Department of Veterans Affairs (VA), Veterans Health Administration, the largest provider of HCV care nationally.
Methods: A 73-item survey was developed and sent to all VA sites treating HCV via electronic survey, to assess
whether or not a site used each ERIC-defined implementation strategy related to employing the new HCV
medication in 2014. VA national data regarding the number of Veterans starting on the new HCV medications at
each site were collected. The associations between treatment starts and number and type of implementation
strategies were assessed.
Results: A total of 80 (62%) sites responded. Respondents endorsed an average of 25 ± 14 strategies. The number
of treatment starts was positively correlated with the total number of strategies endorsed (r = 0.43, p < 0.001).
Quartile of treatment starts was significantly associated with the number of strategies endorsed (p < 0.01), with the
top quartile endorsing a median of 33 strategies, compared to 15 strategies in the lowest quartile. There were
significant differences in the types of strategies endorsed by sites in the highest and lowest quartiles of treatment
starts. Four of the 10 top strategies for sites in the top quartile had significant correlations with treatment starts
compared to only 1 of the 10 top strategies in the bottom quartile sites. Overall, only 3 of the top 15 most
frequently used strategies were associated with treatment.
Conclusions: These results suggest that sites that used a greater number of implementation strategies were able
to deliver more evidence-based treatment in HCV. The current assessment also demonstrates the feasibility of
electronic self-reporting to evaluate ERIC strategies on a large scale. These results provide initial evidence for the
clinical relevance of the ERIC strategies in a real-world implementation setting on a large scale. This is an initial step
in identifying which strategies are associated with the uptake of evidence-based practices in nationwide healthcare
systems.
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Background
A great deal of research now clearly shows that moving
effective programs and practices into routine care settings
requires the skillful use of implementation strategies,
defined as “methods or techniques used to enhance the
adoption, implementation, and sustainability of a clinical
program or practice” [1]. Implementation strategies can
vary widely and their labels can also vary. In order to
generate a common nomenclature for implementation
strategies and facilitate standardization of research
methods in implementation science, the Expert Recom-
mendations for Implementing Change (ERIC) study [2]
engaged experts in modified-Delphi and concept mapping
exercises to (1) refine a compilation of implementation
strategies and (2) develop conceptually distinct categories
of implementation strategies. This led to a compilation of
73 discrete implementation strategies (e.g., access new
funding, audit and provide feedback, facilitation) [3],
which were further organized into nine clusters [3]. These
clusters include changing infrastructure, utilizing financial
strategies, supporting clinicians, providing interactive
assistance, training and educating stakeholders, adapting
and tailoring to the context, developing stakeholder interre-
lationships, using evaluative and iterative strategies, and en-
gaging consumers. This study is the first attempt to
empirically determine whether these strategies and clusters
of strategies are associated with the uptake of evidence-
based practices (EBP) within the US Department of Vet-
erans Affairs (VA), Veterans Health Administration (VHA).
Hepatitis C virus (HCV) infection is a leading cause of
cirrhosis and liver cancer [4] in the USA and in VA. VA is
the single largest provider of HCV care in the USA with
approximately 174,000 Veterans who were potentially
eligible for treatment in 2015 [5]. In the past, HCV treat-
ment required interferon-based therapies, which involved
long courses of injections and had numerous side effects
and contraindications. These barriers resulted in only 23%
of Veterans with HCV ever receiving treatment with these
regimens [6]. Starting in December 2013, the first
interferon-free drug combinations, Direct Acting Antivi-
rals (DAAs), with substantially fewer side effects, shorter
treatment course, and a higher cure rate, were FDA ap-
proved for specific genotypes of HCV. By October 2014
or the start of fiscal year (FY) 2015, interferon-free combi-
nations were available for all genotypes of HCV, making
them the new evidence-based practice for treating HCV
[7–13]. However, these innovative treatments and their
high costs posed a significant challenge to VA, requiring
the healthcare system to adjust policies, resource availabil-
ity, and staffing [6].
Reaching and treating Veterans infected with HCV re-
quired significant restructuring to more rapidly deliver
medications, expand the reach of treatment to Veterans
who were previously ineligible, and bring Veterans into care
who were not previously engaged in care. In order to ac-
complish these goals and facilitate the uptake of the EBP,
VA developed a novel program, the Hepatitis C Innovation
Team Collaborative (HIT). In FY 2015, all 21 regional
administrative centers, or Veterans Integrated Service
Networks (VISNs), were directed to form multidisciplinary
teams. Team members represented multiple sites (e.g.,
medical centers and outpatient clinics) within their region.
Teams were both financially and organizationally supported
to develop strategies, utilizing Lean principles of quality im-
provement [14], to increase treatment rates and improve
access to and quality of HCV care. The engagement
of local providers in the Collaborative varied by site,
and despite the centralized support of providers, local
providers were free to select implementation strat-
egies. The focus of this assessment was on under-
standing which strategies were chosen and the impact
of these strategies on treatment outcomes.
The availability of interferon-free HCV treatments on the
national VA pharmacy formulary, sufficient funding to pro-
vide broad access to these medications, and local flexibility
to choose implementation strategies across the VHA repre-
sented a unique laboratory in which to understand how a
variety of implementation strategies affected the uptake of a
highly evidence-based innovation. We hypothesized that
the number of implementation strategies endorsed would
be associated with increased uptake of the innovation (i.e.,
increased starts of interferon-free medications).
Methods
Overview
We assessed the uptake of strategies as defined by the
ERIC project [2]. To develop the implementation assess-
ment, the original 73 ERIC strategy descriptions were
tailored to interferon-free treatment in VA and the strat-
egies were organized by cluster. The survey was iteratively
vetted by HIT leader stakeholders, five HCV treatment
providers, and a psychometrician for readability and
understandability. Care was taken to ensure fidelity to the
original, previously defined strategies. Table 1 shows the
questions in order of presentation organized by cluster.
The survey asked about strategies used in fiscal year 2015
(FY15) to increase interferon-free HCV treatment at their
VA medical center (VAMC). For each strategy, partici-
pants were asked, “Did you use X strategy to promote
HCV care in your center?” The questions were anchored
to FY15 so they could be linked to treatment data over
the same time period. The Pittsburgh VA IRB determined
that the initiative was exempt under a provision applying
to quality improvement. This assessment was approved as
a quality improvement project by the VA’s HIV, Hepatitis
and Related Conditions Programs in the Office of
Specialty Care Services as a part of the HIT Collaborative
evaluation. All participation was completely voluntary.
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Table 1 Strategies by cluster and correlation with treatment starts
No. Strategy Sites N (%) Correlation P
value
In FY15 did your center use any of these infrastructure changes to promote HCV care in your center?
1 Change physical structure and equipment (e.g., purchase a FibroScan, expand clinic space, open new
clinics)
42 (53) 0.36 <0.01
2 Change the record systems (e.g., locally create new or update to national clinical reminder in CPRS, develop
standardized note templates)
57 (71) −0.02 0.89
3 Change the location of clinical service sites (e.g., extend HCV care to the CBOCs) 21 (26) 0.36 <0.01
4 Develop a separate organization or group responsible for disseminating HCV care (outside of the HIT
Collaborative)
18 (23) 0.21 0.07
5 Mandate changes to HCV care (e.g., when you changed to the new HCV medications was this based
on a leadership mandate?)
44 (55) 0.05 0.69
6 Create or change credentialing and/or licensure standards (e.g., change scopes of practice or service
agreements)
23 (29) 0.01 0.92
7 Participate in liability reform efforts that make clinicians more willing to deliver the clinical
innovation
3 (4) 0.23 0.04
8 Change accreditation or membership requirements 3 (4) 0.23 0.04
In FY15 did your center use any of these financial strategies to promote HCV care in your
center?
9 Access new funding (This DOES NOT include funding from national VA for the medications, but
should include receiving funds from the HIT Collaborative to your center)
24 (30) 0.20 0.08
10 Alter incentive/allowance structures 4 (5) 0.04 0.76
11 Provide financial disincentives for failure to implement or use the clinical innovations 0 . .
12 Respond to proposals to deliver HCV care (e.g., submit a HIT proposal to obtain money for your
center specifically)
35 (44) 0.19 0.11
13 Change billing (e.g., create new clinic codes for billing for HCV treatment or HCV education) 9 (11) 0.17 0.15
14 Place HCV medications on the formulary 56 (70) −0.05 0.67
15 Alter patient fees 0
16 Use capitated payments 0
17 Use other payment schemes 4 (5) 0.22 0.06
18 Create new clinical teams (e.g., interdisciplinary clinical working groups) 37 (46) 0.25 0.04
19 Facilitate the relay of clinical data to providers (e.g., provide outcome data to providers) 45 (56) 0.20 0.09
20 Revise professional roles (e.g., allow the pharmacist to see and treat patients in the clinic) 57 (71) 0.24 0.04
21 Develop reminder systems for clinicians (e.g., use CPRS reminders) 27 (34) −0.16 0.19
22 Develop resource sharing agreements (e.g., partner with the VERC, the HITs, or other
organizations with the resources to help implement changes)
21 (26) 0.24 0.04
In FY15 did your center employ any of these activities to provide interactive assistance
to promote HCV care in your center?
23 Use outside assistance often called “facilitation” (e.g., coaching, education, and/or feedback from
the facilitator)
6 (8) 0.16 0.17
24 Have someone from inside the clinic or center (often called “local technical assistance”)
tasked with assisting the clinic
12 (15) 0.38 <0.01
25 Provide clinical supervision (e.g., train providers) 35 (44) 0.29 0.01
26 Use a centralized system (i.e., from the VISN) to deliver facilitation 22 (28) 0.38 <0.01
In FY15 did your center employ any of these activities to tailor HCV care in your center?
27 Use data experts to manage HCV data (e.g., use the VERC, pharmacy benefits management, VISN,
or CCR data experts to track patients or promote care)
46 (58) 0.18 0.12
28 Use data warehousing techniques (e.g., dashboard, clinical case registry, CDW) 68 (85) 0.15 0.19
29 Tailor strategies to deliver HCV care (i.e., alter HCV care to address barriers to care that you identified
in your population using data you collected)
50 (63) 0.21 0.08
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Table 1 Strategies by cluster and correlation with treatment starts (Continued)
30 Promote adaptability (i.e., Identify the ways HCV care can be tailored to meet local needs and clarify
which elements of care must be maintained to preserve fidelity)
44 (55) 0.16 0.17
In FY15 did your center employ any of these activities to train or educate providers to
promote HCV care in your center?
31 Conduct educational meetings 41 (51) 0.24 0.05
32 Have an expert in HCV care meet with providers to educate them 33 (41) 0.34 <0.01
33 Provide ongoing HCV training 39 (49) 0.26 0.03
34 Facilitate the formation of groups of providers and fostered a collaborative learning
environment
35 (44) 0.38 <0.01
35 Developed formal educational materials 31 (39) 0.00 0.97
36 Distribute educational materials (e.g., guidelines, manuals, or toolkits) 44 (55) 0.11 0.35
37 Provide ongoing consultation with one or more HCV treatment experts 46 (58) 0.11 0.37
38 Train designated clinicians to train others (e.g., primary care providers, SCAN-ECHO) 16 (20) −0.07 0.56
39 Vary the information delivery methods to cater to different learning styles when
presenting new information
29 (36) 0.29 0.02
40 Give providers opportunities to shadow other experts in HCV 26 (33) 0.12 0.32
41 Use educational institutions to train clinicians 9 (11) 0.21 0.07
In FY15 did your center employ any of these activities to develop stakeholder
interrelationships to promote HCV care in your center?
42 Build a local coalition/team to address challenges 42 (53) 0.27 0.03
43 Conduct local consensus discussions (i.e., determine how to change things by having
meetings with local leaders and providers)
38 (48) 0.42 <0.01
44 Obtain formal written commitments from key partners that state what they will do to
implement HCV care (e.g., written agreements with CBOCS)
3 (4) 0.20 0.09
45 Recruit, designate, and/or train leaders 21 (26) 0.29 0.01
46 Inform local opinion leaders about advances in HCV care 39 (49) 0.33 <0.01
47 Share the knowledge gained from quality improvement efforts with other sites outside
your medical center
30 (38) 0.32 <0.01
48 Identify and prepare champions (i.e., select key individuals who will dedicate themselves
to promoting HCV care)
40 (50) 0.29 0.01
49 Organize support teams of clinicians who are caring for patients with HCV and given them time
to share the lessons learned and support one another’s learning
21 (26) 0.16 0.18
50 Use advisory boards and interdisciplinary workgroups to provide input into HCV policies and
elicit recommendations
21 (26) 0.09 0.46
51 Seek the guidance of experts in implementation 35 (44) −0.01 0.92
52 Build on existing high-quality working relationships and networks to promote information
sharing and problem solving related to implementing HCV care
49 (61) 0.24 0.04
53 Use modeling or simulated change 10 (13) 0.25 0.04
54 Partner with a university to share ideas 11 (14) 0.27 0.02
55 Make efforts to identify early adopters to learn from their experiences 13 (16) 0.32 <0.01
56 Visit other sites outside your medical center to try to learn from their experiences 12 (15) 0.30 0.01
57 Develop an implementation glossary 2 (3) 0.17 0.15
58 Involve executive boards 18 (23) 0.15 0.21
In FY15 did your center employ any of these evaluative and iterative strategies to promote
HCV care in your center?
2 (3)
59 Assess for readiness and identify barriers and facilitators to change (e.g., administer the organizational
readiness to change survey)
21 (26) 0.16 0.20
60 Conduct a local needs assessment (i.e., collect data to determine how best to change things) 36 (45) 0.12 0.31
61 Develop a formal implementation blueprint (i.e., make a written plan of goals and strategies) 27 (34) 0.11 0.37
62 Start with small pilot studies and then scale them up 18 (23) 0.08 0.50
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Participation sites and recruitment
The HIT Collaborative provided the contact information
for VA HCV providers and HIT members representing
all 130 individual VA sites. The sites, for the purpose of
this assessment, were defined as all VA medical “sta-
tions” as classified by Population Health Services of the
VA. These stations include a larger medical center, and
some of these stations have smaller satellite sites. All
sites within a station would be included in the measures
of treatment starts for the station. However, most of the
treatment starts are coordinated by and occur in the lar-
ger medical center within these stations. This assessment
included all stations, herein deemed “sites,” regardless of
participation in the HIT Collaborative. Respondents
were surveyed via an email link to an online survey
portal. A modified Dillman approach [15] was used to
promote high response, with two mass emails and one
individual email to reach potential participants. In order
to maximize survey completion rates, the recruitment
email was cosigned by the HIT Collaborative Leadership
team. Additionally, the Leadership Team provided coor-
dinated communication with HIT members on regularly
scheduled calls so that providers were aware of the
assessment and its purpose.
At sites with multiple respondents, we assessed inter-
rater reliability but ultimately retained one respondent
per site. The retention of one respondent was based on
the “key informant” technique, [16] in part to reduce
bias of increased reporting from the sites with duplicate
responses. If an HCV lead clinician, designated by the
VAMC, was available and responded, their answer was
retained; otherwise, if there were multiple respondents,
they were prioritized by who would know the most
about HCV treatment in the following order (established
a priori): physician, pharmacist, advanced practice
provider (nurse practitioner or physician assistant), other
provider, and system redesign staff.
Measures and data collection
The primary outcome of interest was the number of
Veterans started on the new interferon-free medications
for HCV during FY15 from each VAMC (deemed “treat-
ment starts”), which was obtained from VA’s population
health intranet database [5]. A secondary outcome was
the proportion of viremic patients so treated, assessed
by dividing the number of patients started on the medi-
cations by the number of Veterans with known active
HCV infection in need of treatment at each site. VA uses
a Clinical Case Registry to validate HCV cases at each
site, and the numbers are reported nationally. A local
coordinator is sent the results of patients who are found
to be HCV positive and the coordinator at that site
determines whether the patient truly has HCV. Veterans
are considered to be viremic if they have a positive viral
load on their most recent testing, are alive at the end of
the year of interest, and have been validated as HCV
positive through the CCR. In order to be a part of a site’s
patient load, they had to be considered “in care,” mean-
ing that they needed to have had an encounter or
medication fill within the prior 365 days at that medical
facility. Descriptive statistics were used to describe the
frequency of strategy and cluster endorsement and the
Table 1 Strategies by cluster and correlation with treatment starts (Continued)
63 Collect and summarize clinical performance data and give it to clinicians and administrators
to implement changes in a cyclical fashion using small tests of change before making
system-wide changes
17 (21) 0.25 0.04
64 Conduct small tests of change, measured outcomes, and then refined these tests 15 (19) 0.11 0.36
65 Develop and use tools for quality monitoring (this includes standards, protocols and measures to
monitor quality)
33 (41) 0.07 0.56
66 Develop and organize systems that monitor clinical processes and/or outcomes for the purpose
of quality assurance and improvement (i.e., create an overall system for monitoring quality–not
just tools to use in quality monitoring, which is addressed in the last item)
24 (30) 0.18 0.14
67 Intentionally examine the efforts to promote HCV care 49 (61) 0.08 0.49
68 Develop strategies to obtain and use patient and family feedback 16 (20) −0.11 0.35
In FY15 did your center employ any of these strategies to engage patient consumers to
promote HCV care in your center?
69 Involve patients/consumers and family members 40 (50) 0.01 0.91
70 Engage in efforts to prepare patients to be active participants in HCV care (e.g., conduct education sessions to teach
patients about what questions to ask about HCV treatment)
50 (63) 0.39 <0.01
71 Intervene with patients/consumers to promote uptake and adherence to HCV treatment 57 (71) 0.08 0.51
72 Use mass media (e.g., local public service announcements; magazines like VANGUARD, newsletters, online/social
media outlets) to reach large numbers of people
14 (18) 0.00 0.98
73 Promote demand for HCV care among patients through any other means 32 (40) 0.19 0.12
Statistically significant strategies are represented in italics
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association between strategy use and medication starts.
Data were analyzed as follows: (1) the total number of
strategies and (2) the number of strategies within a clus-
ter. As described in Waltz et al. [17], strategies were
grouped into quadrants via combinations of importance
(i.e., how vital a strategy was rated to be in improving
implementation, grouped into low and high categories)
and feasibility (i.e., how possible a certain strategy is to
do, also grouped in to low and high categories). Using
the definitions per Waltz et al., these quadrants included
high feasibility/high importance strategies (quadrant 1),
low importance/high feasibility (quadrant 2), low
importance/low feasibility (quadrant 3), and high
importance/low feasibility (quadrant 4) [3].
A key covariate used in the analyses is “site complex-
ity.” Site complexity in VA was assessed using ratings
from the VHA Facility Complexity Model. First created
in 1989 and regularly updated [18], the ratings combine
site level of care acuity, services available, research
dollars, and patients served. The ratings include
standardized classifications into levels 1a, 1b, 1c, 2, and
3, in decreasing levels of complexity. Thus, level 1a
facilities have high volume, high-risk patients, the most
complex clinical programs, and largest teaching and re-
search programs, and level 3 programs have low volume,
low-risk patients, few or no complex clinical programs,
and small or no research or teaching programs [18]. We
had conducted a prior survey of the programs treating
HCV, asking respondents to self-report the number of
providers treating HCV at each VA site. These data were
added to the dataset in order to determine whether
staffing related to treatment starts and the proportion of
viremic patients treated.
Data analysis
All analyses were conducted using the R statistical package.
Non-parametric statistical tests were used to assess the
associations between dependent and independent variables
including Wilcoxon rank-sum testing for treatment by
strategy and Spearman’s correlation testing for continuous
variables. Interrater reliability was calculated for sites with
duplicate responses. We analyzed whether treatment was
associated with using high-feasibility or high-importance
strategies and also strategies in the “Go-zone” of high
feasibility and importance (zone 1). A multivariable linear
regression model was made to assess whether treatment
starts were associated with implementation strategies,
controlling for facility characteristics.
Results
Of 130 unique stations that are engaged in HCV treat-
ment in VA contacted for the assessment, 80 provided
responses (62%). These 80 sites were responsible for 68%
of national HCV treatment starts in FY15 (n = 20,503).
A total of 133 responses were obtained; 53 were omitted
from further analysis (15 opened the survey and did not
respond to any questions, 29 were duplicate responses
from 19 sites, and 9 did not list an associated VAMC
and could not be linked to outcomes). Among responses
within 19 duplicate sites, interrater reliability was 0.66.
All 21 VA-defined regions of the country (VISNs, as
defined in FY15) were represented. Table 2 illustrates
respondent characteristics and shows that respondents
were predominantly from specialty services of gastro-
enterology/hepatology or infectious disease. Pharmacists
made up the largest group of respondents. There were
no significant associations between participant charac-
teristics and treatment starts or number of strategies
used. The majority of sites represented were complexity
level 1 (Table 2). In addition to standard complexity
scoring, we analyzed the number of providers treating
HCV during the FY of interest from a prior assessment.
These data were available for 49 of the sites (61%). The
median number of providers treating HCV in these sites
was 5 (3,7), including physicians, advanced practitioners,
pharmacists, and nurses.
Table 2 Respondent characteristics
Characteristic N (sites) Percentage
Years in VA
<3 13 16
4 to 9 25 31
10 to 19 25 31
>20 17 21
Specialty
Gastroenterology/hepatology 33 41
Infectious disease 17 21
Pharmacy 13 16
Primary care 8 10
Other (VERC, transplant) 9 11
Degree
PharmD 35 44
NP 13 16
MD 11 14
PA 5 6
RN 2 3
Other 14 18
Site complexity
1a 27 33
1b 14 18
1c 12 15
2 14 18
3 12 15
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Among responding sites, the median number of treat-
ment starts was 197 (IQR = 124, 312). The median num-
ber of Veterans potentially eligible for treatment at the
start of FY15 at these sites was 1149 (IQR = 636, 1744).
The proportion of viremic patients treated ranged from
6 to 47%, with a mean (SD) of 20 ± 8%. The sites that
did not respond had a median number of treatment
starts of 142 (IQR = 88, 296), which was not significantly
different from responding sites (p = 0.07). The median
number of Veterans potentially eligible for treatment at
the start of FY15 at these non-responding sites was 874
(IQR = 494, 1716), which was not significantly different
than responding sites (p = 0.43). The proportion of
viremic patients treated ranged from <1–46%, with a
mean of 17 ± 10%, which was not statistically different
than responding sites (p = 0.15).
Table 1 shows the strategies in order of presentation
on the survey with the questions as they were asked.
Sites endorsed between 1 and 59 strategies, with an
average of 25 ± 14. Quartile of treatment starts was
significantly associated with the number of strategies
endorsed (p < 0.01), with the top quartile endorsing a
median of 33 strategies, compared to 15 strategies in the
lowest quartile. Table 1 shows the frequency of the strat-
egy endorsement, and the association between strategies
and treatment starts. The most frequently used strategies
included data warehousing techniques, (e.g., using a dash-
board; 85%), and intervening with patients to promote
uptake and adherence to HCV treatment (71%).
A total of 28 of the 73 specific strategies were associated
with treatment starts (Table 1, in bold). Associations
between treatment starts and strategies were assessed with
correlation coefficients and Wilcoxon rank-sum tests in
order to assess for stability of results. Notably, the strat-
egies that were significant were consistent regardless of
the type of statistical test applied. Sites using at least 15 of
these significant strategies (n = 20) had increased median
treatment starts (320 vs. 177, p < 0.001). There was a mod-
erate, positive correlation between overall total number of
strategies and treatment starts, which was statistically
significant (r = 0.43, p < 0.001). The strategies most corre-
lated with medication initiations were “conduct local
consensus discussions” (0.42, p < 0.001), “engage in efforts
to prepare patients to be active participants in HCV care”
(0.39, p < 0.001), “facilitate the formation of groups of
providers and [foster] a collaborative learning environ-
ment” (0.38, p = 0.001), “use a centralized system to deliver
facilitation” (0.38, p = 0.001), “have someone from inside
the clinic or center (often called local technical assistance)
tasked with assisting the clinic” (0.38, p = 0.001), “revise
professional roles” (0.36, p = 0.053), “conduct local con-
sensus discussions” (0.36, p = 0.002), “change physical
structure and equipment” (0.36, p = 0.002), and “change
location of clinical service sites” (0.36, p = 0.001). The
strategies were from different clusters, though there were
two strategies each from the interactive assistance and
infrastructure change clusters.
In order to assess the impact of strategies on treat-
ment starts while accounting for facility characteristics,
a multivariable model was made assessing whether the
number of strategies used remained associated with
treatment while controlling for facility complexity. In
this regression model, facility complexity and number of
strategies were both significantly associated with treat-
ment starts. The adjusted R2 for the model was 30%.
The individual strategies were assessed by cluster to
determine the relationships between clusters of strat-
egies and treatment starts. Figure 1 shows the frequency
with which strategies were endorsed by cluster.
Table 3 shows that the number of strategies used
within a cluster was also significantly associated with
treatment starts for each individual cluster. The clusters
with the highest proportion of significant strategies were
“provide interactive assistance” (75% of strategies signifi-
cantly associated with treatment) and “develop stake-
holder interrelationships” (64% of strategies significantly
associated with treatment) and those with the least were
“tailor to the context” and “financial strategies.” None of
the individual financial strategies or tailoring strategies
were associated with treatment starts. Otherwise, there
was at least one strategy significantly correlated with
number of treatment starts in every cluster (Table 1).
Figure 1 graphically depicts the density of endorse-
ment across clusters. Notably, the most commonly used
strategies were not those most strongly associated with
treatment starts. While “providing interactive assistance”
was the most strongly associated with treatment, this
was among the least-endorsed clusters. Conversely,
“adapting and tailoring to the context” was among the
most highly and densely endorsed clusters but there
were no strategies within this cluster associated with
treatment.
Waltz et al. grouped strategies into quadrants by per-
ceived feasibility (low/high) and importance (low/high),
and a composite score [17]. Table 4 demonstrates how
strategies in these quadrants were used by respondents.
Multiple strategies were applied from each quadrant in-
dicating that perceived low feasibility, as defined in the
ERIC project, was not a barrier to reported uptake of
strategies. Treatment starts were associated with the
number of strategies in all quadrants. The number of
both “high feasibility” and “high importance” strategies
endorsed by sites were associated with number of treat-
ment starts (r = 0.37, p < 0.001 and r = 0.39, p < 0.001,
respectively). However, having a higher proportion of
strategies from the “high importance” or “high feasibil-
ity” groups was not associated with higher treatment
rates. In fact, the raw correlation coefficients were higher
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between treatment starts and the low feasibility quad-
rants’ association with treatment starts than for the high
feasibility quadrants.
Table 5 illustrates the strategies that were most com-
monly endorsed among sites in the high and low quartiles
of treatment starts. Five of the strategies were shared
between the groups (denoted in red in the table), and five
were distinct between the groups of sites. There were differ-
ences in the strategies used by high and low quartile sites:
low quartile sites were more likely to endorse “mandating
change” and “changing the record system” while high
quartile sites were more likely to “change equipment and
physical structures” as well as to “facilitate relay of clinical
data to providers.”
In addition to assessing treatment starts, the proportion
of viremic patients treated was assessed. This measure
was not significantly associated with use of any particular
strategy or cluster, number of strategies used overall, or
with facility complexity or number of providers.
Figure 2 illustrates graphically that there was no drop-
off in participation as the assessment progressed, by
illustrating the responses by number of strategies
endorsed and by order of the assessment. Participants
endorsed as many items at the end of the survey as at
the start of the survey, including participants who
endorsed <5 items. This suggests that there was not a
bias towards selecting items earlier in the assessment.
This figure also graphically illustrates the density of
endorsement by strategy and cluster.
Discussion
Implementation strategies that VA medical centers used
to promote HCV treatment with interferon-free medica-
tions were assessed based on the nomenclature devel-
oped in the ERIC study. Specifically, we explored
whether the ERIC strategies and clusters of strategies
were associated with implementation of an innovative
evidence-based practice, in this case the use of
Fig. 1 Endorsement of strategies by cluster
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interferon-free medications for HCV. The use of
interferon-free medications for HCV is highly evidence-
based, is uniformly and simply applied, widely imple-
mented, and easily documented and extractable from the
medical record in a reliable fashion. This makes the use
of interferon-free medications for HCV an ideal case in
which to understand how implementation strategies
function in a real-world context on a large scale. The
presented data suggest that the ERIC strategies are em-
pirically related to the use of interferon-free medications
in a large, nationwide, scale-up effort to increase the
uptake of this evidence-based practice. These data
support the hypothesis that the use of more strategies is
associated with increased use of interferon-free medica-
tions for HCV.
However, the most commonly used strategies and
clusters of strategies were not those associated with the
highest number of treatment starts. Only 3 of the top-
endorsed 15 strategies were correlated with treatment
starts. These included the following strategies: “revise
professional roles,” “build on existing high-quality work-
ing relationships and networks to promote information
sharing and problem solving,” and “engage in efforts to
prepare patients to be active participants.” Whether the
12 non-correlated strategies serve meaningful supportive
roles for those strategies that do correlate with treatment
starts (i.e., that they may be necessary but not sufficient)
is unknown. The clusters with the highest percentage of
strategies associated with treatment rates were “provid-
ing interactive assistance,” “supporting clinicians,” and
“developing stakeholder interrelationships.” The import-
ance of these kinds of interactive and supportive strat-
egies is consistent with the literature on implementation
“facilitation,” in which outside aid is provided to help
sites with a wide range of activities needed to start new
initiatives [19]. Overall sites used multiple strategies
including those that were previously identified as less
feasible by implementation researchers and clinical man-
agers [3]. In fact, the two “low feasibility” quadrants
(both high and low importance) had numerically higher
correlations with treatment starts than the “high feasibil-
ity” quadrants. It is possible that the sites able to con-
duct more difficult and complex (i.e., less feasible)
implementations strategies, including interactive assist-
ance, were able to treat more patients. Additionally,
these findings may indicate that feasibility and
Table 3 Correlation between items endorsed in the cluster and treatment starts
Implementation
strategy clusters
Number
of strategies
Number of Endorsements
(number per strategy in
cluster)
Correlation between number
of strategies used within the
cluster and treatment starts
R2 P value Number (%) of strategies in
the cluster associated with
treatment starts
Provide interactive assistance 4 75 (19) 0.46 21% <0.001 3 (75%)
Develop stakeholder
relationships
17 405 (24) 0.44 20% <0.001 11 (64%)
Train and educate stakeholders 11 349 (32) 0.33 11% 0.003 5 (45%)
Adapt and tailor to context 4 208 (52) 0.31 10% 0.004 0 (0%)
Change infrastructure 8 211 (26) 0.29 9% 0.008 4 (50%)
Support clinicians 5 187 (37) 0.29 8% 0.009 3 (60%)
Engage consumer 5 193 (39) 0.27 7% 0.016 1 (20%)
Financial strategies 9 141 (16) 0.26 7% 0.020 0 (0%)
Use evaluative and iterative
strategies
10 191 (19) 0.23 5% 0.043 1 (10%)
Table 4 Quadrant assessment
Quadrant Description Number of
strategies
in quadrant
Number of
endorsements
of strategies in
quadrant by
respondents
Endorsements
per strategy
Number of strategies
associated with treatment
starts in quadrant (% of
strategies in quadrant)
Correlation between
number strategies
used in quadrant and
treatment starts r (p)
Correlation between
number strategies
used in quadrant
and number
viremic r (p)
1 High importance,
high feasibility
31 966 31 10 (32%) 0.35 (0.002) 0.38 (<0.001)
2 Low importance,
high feasibility
11 215 20 5 (45%) 0.37 (<0.001) 0.38 (<0.001)
3 Low importance,
low feasibility
22 542 25 9 (41%) 0.44 (<0.001) 0.37 (<0.001)
4 High importance,
low feasibility
9 293 33 4 (44%) 0.44 (<0.001) 0.41 (<0.001)
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importance could vary across innovation, context, and
recipients. An alternative explanation is that the feasibil-
ity of strategies as identified in a theoretical process (as
was ERIC) does not accurately reflect what is applied in
routine clinical implementation. Future research may
need to assess how perceptions of feasibility and import-
ance operate across different clinical contexts.
The data regarding successful strategies are consistent
with prior implementation research regarding efficacy of
specific strategies. For example, “mandating change” was
a strategy often endorsed by the sites in the lowest quar-
tile of treatment and not by the higher treating sites,
which is consistent with prior evidence for the minimal
effectiveness of top-down mandates in implementing
Table 5 Most commonly used strategies in the top and bottom quartile of treatment starts
Top treating quartile Cluster N Quadrant Bottom treating quartile Cluster N Quadrant
Revise professional rolesa Support
clinicians
14 3 Intentionally examine the efforts to
promote HCV care
Evaluative 9 1
Identify and prepare championsa Interrelationships 14 1 Place HCV medications on the
formulary
Financial 13 4
Tailor strategies to deliver HCV care Tailor 15 1 Provide ongoing consultation with one
or more HCV treatment experts
Train/educate 9 1
Engage in efforts to prepare patients
to be active participants in HCV carea
Consumers 16 4 Mandate changes to HCV care Infrastructure 13 3
Change the record systems Infrastructure 14 3 Develop reminder systems for clinicians Support 9 2
Intervene with patients/consumers
to promote uptake and adherence
to HCV treatment
Consumers 17 4 Intervene with patients/consumers to
promote uptake and adherence to
HCV treatment
Consumers 14 4
Use data warehousing techniques Tailor 19 3 Use data warehousing techniques Tailor 16 3
Distribute educational materials Train/educate 14 1 Distribute educational materials Train/educate 9 1
Facilitate the relay of clinical data
to providers
Support 15 1 Facilitate the relay of clinical data
to providers
Support 11 1
Build on existing high-quality working
relationships and networks to promote
information sharing and problem
solving related to implementing
HCV carea
Interrelationships 15 3 Build on existing high-quality working
relationships and networks to promote
information sharing and problem
solving related to implementing
HCV carea
Interrelationships 9 3
aStrategies significantly correlated with treatment starts (see Table 2)
Fig. 2 Strategies in order of presentation on the survey by participant. This density plot represents strategy endorsements made by each
participant in the order in which they were presented in the survey from left to right. Respondents, represented by rows, were sorted by the
number of strategies they endorsed with those endorsing the least at the top of the plot and those endorsing the most at the bottom
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change [20, 21]. Overall, five of the top ten strategies for
the top and bottom quartiles were shared by both
groups. The sites in the highest quartile of treatment
tended to use more interpersonally focused strategies (3
of 5 distinct strategies including “revising professional
roles,” “preparing champions,” and “preparing patients”)
while only 1 of the 5 distinct strategies in the lowest
quartile of treatment was interpersonally focused (e.g.,
“consultation”). However, there were not specific clusters
or quadrants that predicted being in the highest vs.
lowest quartile of treatment.
None of the strategies within the financial cluster were
significantly associated with treatment starts. There are
a variety of financial strategies and several are not
applicable within VA. For example, sites do not have the
flexibility to change billing, provide financial incentives,
use capitated payments, or alter patient fees. Sites do
have the ability to create new clinic codes, for example,
if pharmacists have new clinics, and a few sites endorsed
this item. “Accessing new funding” via grants or the HIT
program and “responding to proposals” were items that
were frequently endorsed by sites. These were not asso-
ciated with treatment starts, possibly because the finan-
cial component provided by the HIT was modest. One
financial strategy of note was adding medications to the
formulary. VA fiscal and formulary changes are nation-
ally applied. Thus, the HCV medications were placed on
the national formulary at the same time for all sites.
However, it is notable that the low treating sites were
more likely to endorse “placing HCV medications on the
formulary” as among their most frequently-used strat-
egies. This is likely a reflection of the lack of other active
local strategies being used in these sites. These sites were
more likely to attribute the national formulary change to
the actions of their site than the sites that were more
active in their implementation.
It is possible that an association between the strategies
used and treatment starts could be due simply to facility
characteristics. For example, larger sites may have more
capacity in the form of staffing and resources to engage
in treatment. However, this was not found in this sam-
ple. The number of staff was not significantly associated
with the number of treatment starts. Similarly, the num-
ber of providers was not significantly correlated with the
number of strategies or the number of significant strat-
egies. More complex medical centers were more likely
to choose the strategies that were significantly associated
with treatment starts. Future work should focus on the
interactions between the types of strategies used and
facility complexity.
This assessment was an example of adapting the ERIC
strategies to a specific clinical issue. While the survey
items maintained fidelity to each of the 73 implementa-
tion strategies in ERIC, they were also tailored to HCV
with specific examples. The process required vetting the
survey with stakeholders to ensure that the examples
were relevant and understandable. Presenting complex
implementation terms in long lists to stakeholders was
found to be feasible with a reasonable response rate in
this national sample. The high interrater reliability
among participants from sites with multiple respondents
suggests that participants are interpreting the strategies
consistently within the sites. However, more qualitative
work will be required to determine how community
stakeholders do or do not distinguish between particular
strategies. This general approach of using a structured
survey could be used to track strategy use over time in
implementation research and practice. Failing to accur-
ately track strategy use limits abilities to explain how
and why specific efforts succeed or fail. This type of
approach could move implementation science towards a
more comprehensive understanding of how various
strategies operate across settings and disease states.
There is currently a paucity of measures to assess imple-
mentation strategy use [22] and this study contributes to
the literature by providing one approach to assess
strategy use through an online survey.
There were several limitations of this evaluation. Des-
pite the fact that this was a national assessment with
high response rates, the total number of respondents
was small compared to the number of strategies that
were investigated, which limited the power to assess
multiple variables in the same models. This was a cross-
sectional assessment and future assessments will allow
us to better understand longitudinal associations of the
strategies with treatment rates over time. Over FY15,
there were multiple national policy shifts that dramatic-
ally and transiently impacted funding for HCV treat-
ment. These changes likely impacted treatment rates,
independent of implementation strategy use. However,
given that these changes occurred on a national level
secular changes would theoretically affect sites uni-
formly. In this investigation we were unable to assess
interactions between policy changes and implementation
strategies, though this would be of interest. While these
assessments within VA allowed us to examine these
implementation strategies in a national system, the
external validity in a non-VA system will need to be
investigated in future studies. The effects of patient
factors, particularly gender, will also need to be assessed,
given the predominance of men in the VA system. While
we chose a key informant technique, using one respond-
ent per center, and had high interrater reliability where
there was more than one respondent, future investiga-
tions should assess who and how to sample stakeholders.
Additionally, the strategies can be interpreted differently
by different stakeholders. For example “placing HCV
medications on the formulary” was interpreted as a site-
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level strategy by some sites and not others, despite the
fact that VA has a national formulary. While treatment
starts were significantly and moderately correlated with
strategies, other factors are likely involved in determin-
ing the number of treatment starts. These likely include
patient factors and unmeasured site factors. It is also
possible that sites employed additional implementation
strategies that were not captured by the ERIC taxonomy
or that they were not able to recall. Also, sites’ endorse-
ments of strategies do not explain how the strategies
were used or the extent of reach. While our methods did
not allow us to understand the sequencing, intensity, or
fidelity to each implementation strategy, the results
demonstrate the feasibility of assessing a wide range of
strategies nationally and the importance of strategy
choice even in the context of a simple and highly
evidence-based practice.
While this study is a first step towards understanding
the role of strategy selection in clinical outcomes, there
are several avenues for future research. Qualitative work
could also help in determining the rationale for strategy
choices and the perceptions of effectiveness. Future re-
search should also assess the effectiveness of directing
sites to specific strategies that have been thoughtfully
selected based upon theory, evidence, and stakeholder
input. In the past, implementation experts have advo-
cated for systematic methods for selecting strategies
based on evidence, theory, and stakeholder input [23].
Additionally an understanding of the cost effectiveness
of specific strategies would certainly add to the field.
Conclusions
This study is a first step towards better understanding
how specific implementation strategies and clusters of
strategies influence the uptake of a highly-evidence
based, uniform innovation. The results demonstrate that
the number of implementation strategies was associated
with a meaningful clinical outcome. These results pro-
vide initial evidence for the clinical relevance of the
ERIC strategies in a real-world setting on a large scale.
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